Val­ne­va re­ports more da­ta on Covid-19 vac­cine; Clin­Choice buys a CRO

Val­ne­va pre­sent­ed up­dates on its Covid-19 vac­cine, the first to get the full mar­ket­ing green light in Eu­rope, but the French biotech stopped man­u­fac­tur­ing of it last year be­cause of re­duced or­der vol­ume in the EU.

The com­pa­ny said it has ex­tend­ed the vac­cine’s shelf life by three months, from 18 to 21 months. It al­so said the Eu­ro­pean Med­i­cines Agency’s com­mit­tee gave a pos­i­tive opin­ion for us­ing the vac­cine, VLA2001, as a boost­er dose in adults 18 to 50 years old.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN